Dr. Reddy’s Zoliflodacin Gets Thai FDA Approval for Gonorrhea Treatment

Nuzolvence becomes a new oral antibiotic option for uncomplicated urogenital gonorrhea

Dr. Reddy’s Laboratories announced that the Thai Food and Drug Administration (FDA) has approved Nuzolvence (zoliflodacin), an oral antibiotic for the treatment of uncomplicated urogenital gonorrhea.

The approval marks an important step in making a new treatment option available to patients in Thailand, particularly as drug-resistant gonorrhea continues to create challenges for healthcare systems.

Nuzolvence was developed through a public-private research and development partnership involving Dr. Reddy’s Laboratories, Innoviva Specialty Therapeutics and the Global Antibiotic Research and Development Partnership (GARDP).

Zoliflodacin was developed through a global R&D partnership

Zoliflodacin is a new oral antibiotic developed to treat uncomplicated urogenital gonorrhea.

The product's development involved several organizations working together to move the medicine through clinical development and regulatory review.

The Phase 3 clinical trial for zoliflodacin was sponsored by GARDP.

Dr. Reddy’s subsidiary, Aurigene Pharmaceutical Services Limited (APSL), also played an important role in advancing the product's development.

The collaboration brought together pharmaceutical research capabilities and global public health expertise to support the development of a new treatment for gonorrhea.

Thailand gives priority to the new antibiotic

The approval in Thailand follows a priority review process.

The product was submitted for priority review in Thailand in November 2025, with support from the GARDP Foundation.

Dr. Reddy’s Laboratories led the regulatory submission strategy and worked with the Thai FDA during the regulatory review process.

The approval now allows Nuzolvence to become an additional oral antibiotic option for uncomplicated urogenital gonorrhea in the country.

Zoliflodacin was previously approved in the United States

The Thai approval follows the US Food and Drug Administration's approval of zoliflodacin earlier this year.

Innoviva Specialty Therapeutics owns the US marketing rights for the therapy.

The latest approval in Thailand expands the regulatory reach of zoliflodacin and represents another step toward making the treatment available in additional markets.

Why a new gonorrhea antibiotic matters

Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae.

The infection can affect the reproductive and urinary systems and may cause symptoms such as painful urination and genital discharge. Some people may not experience noticeable symptoms, which can make detection and treatment more difficult.

One of the biggest concerns for healthcare professionals is the growing resistance of Neisseria gonorrhoeae to commonly used antibiotics.

As bacteria become resistant to existing medicines, treatment options can become more limited.

This makes the development of new antibiotics important, especially for infections caused by multidrug-resistant strains.

Nuzolvence provides an oral treatment option that could help address the need for additional therapies in the management of gonorrhea.

Dr. Reddy’s highlights the importance of the approval

Deepak Sapra, chief executive officer, API and Services, Dr. Reddy’s Laboratories, said the approval of zoliflodacin is an important step toward improving access to an innovative treatment for gonorrhea.

He also highlighted the potential importance of the therapy in addressing infections caused by multidrug-resistant strains.

The company believes the Thai approval can help support timely access to a new treatment option for patients who need effective therapy.

GARDP continues its work against drug-resistant infections

The development of zoliflodacin has been supported by GARDP, an organization focused on developing new antibiotic treatments for drug-resistant bacterial infections.

Antimicrobial resistance is becoming a major global health concern.

When bacteria develop resistance to commonly used antibiotics, infections can become harder to treat and may require more complex medical care.

Gonorrhea is one of the infections where antibiotic resistance has become a growing concern, making new treatment options increasingly important.

The development and regulatory approval of zoliflodacin reflect the wider effort to address this challenge through collaboration between pharmaceutical companies, research organizations and public health groups.

Dr. Reddy’s continues to expand its role in pharmaceutical development

Dr. Reddy’s Laboratories is involved in the development and commercialization of pharmaceutical products across several therapeutic areas.

Through its subsidiary Aurigene Pharmaceutical Services Limited, the company has also supported research and development activities related to innovative medicines.

The approval of Nuzolvence in Thailand adds another regulatory milestone to the development journey of zoliflodacin and strengthens efforts to expand access to new antibiotic treatment options.

With the Thai FDA approval now in place, Nuzolvence becomes another oral treatment option available for uncomplicated urogenital gonorrhea, while the wider global healthcare community continues to address the challenge of antibiotic resistance.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!